Cited by 933Atrial Fibrillation Management and OutcomesAcute Ischemic Stroke ManagementCardiac Arrhythmias and Treatments

The DOI matches its Crossref record, with a small difference in title or year; 1,376 of the 1,396 references it cites were found in a registry or an index.

2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation

Open access

Abstract

AIM The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Patients With Atrial Fibrillation” provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation. METHODS A comprehensive literature search was conducted from May 12, 2022, to November 3, 2022, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate. STRUCTURE Atrial fibrillation is the most sustained common arrhythmia, and its incidence and prevalence are increasing in the United States and globally. Recommendations from the “2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation” and the “2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation” have been updated with new evidence to guide clinicians. In addition, new recommendations addressing atrial fibrillation and thromboembolic risk assessment, anticoagulation, left atrial appendage occlusion, atrial fibrillation catheter or surgical ablation, and risk factor modification and atrial fibrillation prevention have been developed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2023.08.017

Cites

1376 of 1376 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Items 801–1,000 of 1,376

Flagged first, then by citations

20 of the 1396 references couldn’t be matched to a known paper.

Research works printed but not linked: 246

  1. Schnabel, 2015, 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study, Lancet, 386, 154, 10.1016/S0140-6736(14)61774-8 · DOI · Paper page
  2. Mou, 2018, Lifetime risk of atrial fibrillation by race and socioeconomic status: ARIC study (Atherosclerosis Risk in Communities), Circ Arrhythm Electrophysiol, 11, 10.1161/CIRCEP.118.006350 · DOI
  3. Haissaguerre, 1998, Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins, N Engl J Med, 339, 659, 10.1056/NEJM199809033391003 · DOI
  4. Haissaguerre, 1998, Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins, N Engl J Med, 339, 659, 10.1056/NEJM199809033391003 · DOI
  5. Voigt, 2010, Left-to-right atrial inward rectifier potassium current gradients in patients with paroxysmal versus chronic atrial fibrillation, Circ Arrhythm Electrophysiol, 3, 472, 10.1161/CIRCEP.110.954636 · DOI
  6. Lubitz, 2010, Association between familial atrial fibrillation and risk of new-onset atrial fibrillation, JAMA, 304, 2263, 10.1001/jama.2010.1690 · DOI · Paper page
  7. Roselli, 2018, Multi-ethnic genome-wide association study for atrial fibrillation, Nat Genet, 50, 1225, 10.1038/s41588-018-0133-9 · DOI
  8. Lunde, 2018, Associations between socioeconomic status, atrial fibrillation, and outcomes: a systematic review, Expert Rev Cardiovasc Ther, 16, 857, 10.1080/14779072.2018.1533118 · DOI
  9. Kunneman, 2020, Assessment of shared decision-making for stroke prevention in patients with atrial fibrillation: a randomized clinical trial, JAMA Intern Med, 180, 1215, 10.1001/jamainternmed.2020.2908 · DOI
  10. Alonso, 2013, Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium, J Am Heart Assoc, 2
  11. Shang, 2016, Chronic kidney disease and the risk of new-onset atrial fibrillation: a meta-analysis of prospective cohort studies, PLoS One, 11, 10.1371/journal.pone.0155581 · DOI
  12. Perez, 2019, Large-scale assessment of a smartwatch to identify atrial fibrillation, N Engl J Med, 381, 1909, 10.1056/NEJMoa1901183 · DOI · Paper page
  13. Aune, 2018, Tobacco smoking and the risk of atrial fibrillation: a systematic review and meta-analysis of prospective studies, Eur J Prev Cardiol, 25, 1437, 10.1177/2047487318780435 · DOI
  14. Aune, 2018, Diabetes mellitus, blood glucose and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies, J Diabetes Complications, 32, 501, 10.1016/j.jdiacomp.2018.02.004 · DOI
  15. Soliman, 2020, Effect of intensive blood pressure lowering on the risk of atrial fibrillation, Hypertension, 75, 1491, 10.1161/HYPERTENSIONAHA.120.14766 · DOI
  16. Alonso, 2013, Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium, J Am Heart Assoc, 2
  17. Himmelreich, 2020, Prediction models for atrial fibrillation applicable in the community: a systematic review and meta-analysis, Europace, 22, 684, 10.1093/europace/euaa005 · DOI
  18. Roselli, 2018, Multi-ethnic genome-wide association study for atrial fibrillation, Nat Genet, 50, 1225, 10.1038/s41588-018-0133-9 · DOI
  19. Huxley, 2011, Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study, Circulation, 123, 1501, 10.1161/CIRCULATIONAHA.110.009035 · DOI · Paper page
  20. Mishima, 2021, Self-reported physical activity and atrial fibrillation risk: a systematic review and meta-analysis, Heart Rhythm, 18, 520, 10.1016/j.hrthm.2020.12.017 · DOI
  21. Newman, 2021, Risk of atrial fibrillation in athletes: a systematic review and meta-analysis, Br J Sports Med, 55, 1233, 10.1136/bjsports-2021-103994 · DOI · Paper page
  22. Marcus, 2021, Acute consumption of alcohol and discrete atrial fibrillation events, Ann Intern Med, 174, 1503, 10.7326/M21-0228 · DOI
  23. Lu, 2021, Genetically determined tobacco and alcohol use and risk of atrial fibrillation, BMC Med Genomics, 14, 73, 10.1186/s12920-021-00915-0 · DOI
  24. Abed, 2013, Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial, JAMA, 310, 2050, 10.1001/jama.2013.280521 · DOI · Paper page
  25. Pathak, 2015, Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY), J Am Coll Cardiol, 65, 2159, 10.1016/j.jacc.2015.03.002 · DOI · Paper page
  26. Middeldorp, 2018, PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study, Europace, 20, 1929, 10.1093/europace/euy117 · DOI
  27. Di Benedetto, 2018, Individual and combined impact of lifestyle factors on atrial fibrillation in apparently healthy men and women: the EPIC-Norfolk prospective population study, Eur J Prev Cardiol, 25, 1374, 10.1177/2047487318782379 · DOI
  28. Donnellan, 2019, Outcomes of atrial fibrillation ablation in morbidly obese patients following bariatric surgery compared with a nonobese cohort, Circ Arrhythm Electrophysiol, 12, 10.1161/CIRCEP.119.007598 · DOI
  29. Donnellan, 2019, Association between pre-ablation bariatric surgery and atrial fibrillation recurrence in morbidly obese patients undergoing atrial fibrillation ablation, Europace, 21, 1476, 10.1093/europace/euz183 · DOI
  30. Donnellan, 2020, Impact of bariatric surgery on atrial fibrillation type, Circ Arrhythm Electrophysiol, 13, 10.1161/CIRCEP.119.007626 · DOI
  31. Mohanty, 2018, Impact of weight loss on ablation outcome in obese patients with longstanding persistent atrial fibrillation, J Cardiovasc Electrophysiol, 29, 246, 10.1111/jce.13394 · DOI
  32. Hegbom, 2007, Effects of short-term exercise training on symptoms and quality of life in patients with chronic atrial fibrillation, Int J Cardiol, 116, 86, 10.1016/j.ijcard.2006.03.034 · DOI
  33. Malmo, 2016, Aerobic interval training reduces the burden of atrial fibrillation in the short term: a randomized trial, Circulation, 133, 466, 10.1161/CIRCULATIONAHA.115.018220 · DOI · Paper page
  34. Elliott, 2023, An exercise and physical activity program in patients with atrial fibrillation: the ACTIVE-AF randomized controlled trial, J Am Coll Cardiol EP, 9, 455
  35. Pathak, 2015, Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT study, J Am Coll Cardiol, 66, 985, 10.1016/j.jacc.2015.06.488 · DOI · Paper page
  36. Oesterle, 2022, Effects of supervised exercise training on atrial fibrillation: a meta-analysis of randomized controlled trials, J Cardiopulm Rehabil Prev, 42, 258, 10.1097/HCR.0000000000000665 · DOI
  37. Osbak, 2011, A randomized study of the effects of exercise training on patients with atrial fibrillation, Am Heart J, 162, 1080, 10.1016/j.ahj.2011.09.013 · DOI
  38. Andersen, 2013, Risk of arrhythmias in 52 755 long-distance cross-country skiers: a cohort study, Eur Heart J, 34, 3624, 10.1093/eurheartj/eht188 · DOI · Paper page
  39. Arnett, 2019, 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, J Am Coll Cardiol, 74, e177, 10.1016/j.jacc.2019.03.010 · DOI · Paper page
  40. Voskoboinik, 2020, Alcohol abstinence in drinkers with atrial fibrillation, N Engl J Med, 382, 20, 10.1056/NEJMoa1817591 · DOI
  41. Marcus, 2022, Individualized studies of triggers of paroxysmal atrial fibrillation: the I-STOP-AFib randomized clinical trial, JAMA Cardiol, 7, 167, 10.1001/jamacardio.2021.5010 · DOI
  42. Marcus, 2021, Acute consumption of alcohol and discrete atrial fibrillation events, Ann Intern Med, 174, 1503, 10.7326/M21-0228 · DOI
  43. Abed, 2013, Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial, JAMA, 310, 2050, 10.1001/jama.2013.280521 · DOI · Paper page
  44. Pathak, 2014, Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study, J Am Coll Cardiol, 64, 2222, 10.1016/j.jacc.2014.09.028 · DOI · Paper page
  45. Pathak, 2015, Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY), J Am Coll Cardiol, 65, 2159, 10.1016/j.jacc.2015.03.002 · DOI · Paper page
  46. Middeldorp, 2018, PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study, Europace, 20, 1929, 10.1093/europace/euy117 · DOI
  47. Marcus, 2022, Individualized Studies of triggers of paroxysmal atrial fibrillation: the I-STOP-AFib randomized clinical trial, JAMA Cardiol, 7, 167, 10.1001/jamacardio.2021.5010 · DOI
  48. Abed, 2013, Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial, JAMA, 310, 2050, 10.1001/jama.2013.280521 · DOI · Paper page
  49. Pathak, 2015, Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY), J Am Coll Cardiol, 65, 2159, 10.1016/j.jacc.2015.03.002 · DOI · Paper page
  50. Donnellan, 2019, Association between pre-ablation glycemic control and outcomes among patients with diabetes undergoing atrial fibrillation ablation, J Am Coll Cardiol EP, 5, 897
  51. Neefs, 2017, Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and meta-analysis, Int J Cardiol, 231, 155, 10.1016/j.ijcard.2016.12.029 · DOI · Paper page
  52. Steinberg, 2020, Effect of renal denervation and catheter ablation vs catheter ablation alone on atrial fibrillation recurrence among patients with paroxysmal atrial fibrillation and hypertension: the ERADICATE-AF randomized clinical trial, JAMA, 323, 248, 10.1001/jama.2019.21187 · DOI · Paper page
  53. Pathak, 2014, Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study, J Am Coll Cardiol, 64, 2222, 10.1016/j.jacc.2014.09.028 · DOI · Paper page
  54. Pinho-Gomes, 2021, Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: an individual participant data meta-analysis, PLoS Med, 18, 10.1371/journal.pmed.1003599 · DOI
  55. Parkash, 2017, Effect of aggressive blood pressure control on the recurrence of atrial fibrillation after catheter ablation: a randomized, open-label clinical trial (SMAC-AF [Substrate Modification With Aggressive Blood Pressure Control]), Circulation, 135, 1788, 10.1161/CIRCULATIONAHA.116.026230 · DOI · Paper page
  56. Soliman, 2020, Effect of intensive blood pressure lowering on the risk of atrial fibrillation, Hypertension, 75, 1491, 10.1161/HYPERTENSIONAHA.120.14766 · DOI
  57. Pathak, 2015, Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY), J Am Coll Cardiol, 65, 2159, 10.1016/j.jacc.2015.03.002 · DOI · Paper page
  58. Li, 2021, Effects of continuous positive airway pressure treatment in obstructive sleep apnea patients with atrial fibrillation: a meta-analysis, Medicine (Baltimore), 100
  59. Yang, 2020, CPAP is associated with decreased risk of AF recurrence in patients with OSA, especially those younger and slimmer: a meta-analysis, J Interv Card Electrophysiol, 58, 369, 10.1007/s10840-020-00738-6 · DOI
  60. Congrete, 2018, Effect of obstructive sleep apnea and its treatment of atrial fibrillation recurrence after radiofrequency catheter ablation: a meta-analysis, J Evid Based Med, 11, 145, 10.1111/jebm.12313 · DOI
  61. Deng, 2018, Treating obstructive sleep apnea with continuous positive airway pressure reduces risk of recurrent atrial fibrillation after catheter ablation: a meta-analysis, Sleep Med, 46, 5, 10.1016/j.sleep.2018.02.013 · DOI
  62. Qureshi, 2015, Meta-analysis of continuous positive airway pressure as a therapy of atrial fibrillation in obstructive sleep apnea, Am J Cardiol, 116, 1767, 10.1016/j.amjcard.2015.08.046 · DOI
  63. Szymanski, 2015, Presence and severity of obstructive sleep apnea and remote outcomes of atrial fibrillation ablations - a long-term prospective, cross-sectional cohort study, Sleep Breath, 19, 849, 10.1007/s11325-014-1102-x · DOI · Paper page
  64. Caples, 2019, The impact of continuous positive airway pressure treatment on the recurrence of atrial fibrillation post cardioversion: a randomized controlled trial, Int J Cardiol, 278, 133, 10.1016/j.ijcard.2018.11.100 · DOI · Paper page
  65. Traaen, 2021, Effect of continuous positive airway pressure on arrhythmia in atrial fibrillation and sleep apnea: a randomized controlled trial, Am J Respir Crit Care Med, 204, 573, 10.1164/rccm.202011-4133OC · DOI
  66. Hunt, 2022, Effect of continuous positive airway pressure therapy on recurrence of atrial fibrillation after pulmonary vein isolation in patients with obstructive sleep apnea: a randomized controlled trial, Heart Rhythm, 19, 1433, 10.1016/j.hrthm.2022.06.016 · DOI
  67. Voskoboinik, 2020, Alcohol abstinence in drinkers with atrial fibrillation, N Engl J Med, 382, 20, 10.1056/NEJMoa1817591 · DOI
  68. Abed, 2013, Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial, JAMA, 310, 2050, 10.1001/jama.2013.280521 · DOI · Paper page
  69. Rienstra, 2018, Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial, Eur Heart J, 39, 2987, 10.1093/eurheartj/ehx739 · DOI · Paper page
  70. Hlatky, 2009, Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association, Circulation, 119, 2408, 10.1161/CIRCULATIONAHA.109.192278 · DOI
  71. Rao, 2015, Blood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial, J Am Heart Assoc, 4
  72. Steinberg, 2015, Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial, Eur Heart J, 36, 288, 10.1093/eurheartj/ehu359 · DOI
  73. Chao, 2018, Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors, Thromb Haemost, 118, 768, 10.1055/s-0038-1636534 · DOI
  74. Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 · DOI · Paper page
  75. Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 · DOI · Paper page
  76. Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 · DOI · Paper page
  77. Giugliano, 2013, Edoxaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 369, 2093, 10.1056/NEJMoa1310907 · DOI · Paper page
  78. Singer, 2013, A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score, J Am Heart Assoc, 2
  79. Gage, 2001, Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation, JAMA, 285, 2864, 10.1001/jama.285.22.2864 · DOI · Paper page
  80. Buck, 2021, Effect of implantable vs prolonged external electrocardiographic monitoring on atrial fibrillation detection in patients with ischemic stroke: the per diem randomized clinical trial, JAMA, 325, 2160, 10.1001/jama.2021.6128 · DOI
  81. Eckman, 2011, Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation, Circ Cardiovasc Qual Outcomes, 4, 14, 10.1161/CIRCOUTCOMES.110.958108 · DOI
  82. Gutiérrez, 2020, Beneficial effect of left atrial appendage closure during cardiac surgery: a meta-analysis of 280 585 patients, Eur J Cardiothorac Surg, 57, 252
  83. Holmes, 2014, Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial, J Am Coll Cardiol, 64, 1, 10.1016/j.jacc.2014.04.029 · DOI
  84. Reddy, 2017, 5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials, J Am Coll Cardiol, 70, 2964, 10.1016/j.jacc.2017.10.021 · DOI
  85. Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 · DOI · Paper page
  86. Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 · DOI · Paper page
  87. Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 · DOI · Paper page
  88. Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 · DOI · Paper page
  89. Giugliano, 2013, Edoxaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 369, 2093, 10.1056/NEJMoa1310907 · DOI · Paper page
  90. López-López, 2017, Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis, BMJ, 359, j5058, 10.1136/bmj.j5058 · DOI
  91. Ruff, 2014, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, Lancet, 383, 955, 10.1016/S0140-6736(13)62343-0 · DOI · Paper page
  92. Brokmeier, 2021, Off-label use for direct oral anticoagulants: valvular atrial fibrillation, heart failure, left ventricular thrombus, superficial vein thrombosis, pulmonary hypertension-a systematic review, Ann Pharmacother, 55, 995, 10.1177/1060028020970618 · DOI
  93. Hart, 2007, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Ann Intern Med, 146, 857, 10.7326/0003-4819-146-12-200706190-00007 · DOI · Paper page
  94. Sanna, 2014, Cryptogenic stroke and underlying atrial fibrillation, N Engl J Med, 370, 2478, 10.1056/NEJMoa1313600 · DOI · Paper page
  95. Kirchhof, 2020, Early rhythm-control therapy in patients with atrial fibrillation, N Engl J Med, 383, 1305, 10.1056/NEJMoa2019422 · DOI
  96. Van Gelder, 2010, Lenient versus strict rate control in patients with atrial fibrillation, N Engl J Med, 362, 1363, 10.1056/NEJMoa1001337 · DOI · Paper page
  97. Connolly, 2011, Dronedarone in high-risk permanent atrial fibrillation, N Engl J Med, 365, 2268, 10.1056/NEJMoa1109867 · DOI
  98. Ulimoen, 2013, Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation, Am J Cardiol, 111, 225, 10.1016/j.amjcard.2012.09.020 · DOI · Paper page
  99. Nikolaidou, 2009, Chronic atrial fibrillation: a systematic review of medical heart rate control management, Postgrad Med J, 85, 303, 10.1136/pgmj.2008.068908 · DOI · Paper page
  100. Hohnloser, 2009, Effect of dronedarone on cardiovascular events in atrial fibrillation, Revista Portuguesa de Cardiologia, 28, 345
  101. Brignole, 1998, Atrioventricular junction ablation and pacemaker therapy versus drug treatment in atrial fibrillation, Cardiol Rev, 15, 49
  102. D, 2009, Survival of dual chamber pacing post atrioventricular nodal ablation in patients with atrial fibrillation, Heart Rhythm, 6, S406
  103. Santhanakrishnan, 2016, Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction, Circulation, 133, 484, 10.1161/CIRCULATIONAHA.115.018614 · DOI
  104. Van Gelder, 2010, Lenient versus strict rate control in patients with atrial fibrillation, N Engl J Med, 362, 1363, 10.1056/NEJMoa1001337 · DOI · Paper page
  105. Andrade, 2021, Cryoablation or drug therapy for initial treatment of atrial fibrillation, N Engl J Med, 384, 305, 10.1056/NEJMoa2029980 · DOI
  106. Kirchhof, 2020, Early rhythm-control therapy in patients with atrial fibrillation, N Engl J Med, 383, 1305, 10.1056/NEJMoa2019422 · DOI
  107. Kim, 2021, Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study, BMJ, 373, n991, 10.1136/bmj.n991 · DOI
  108. Pathak, 2015, Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY), J Am Coll Cardiol, 65, 2159, 10.1016/j.jacc.2015.03.002 · DOI · Paper page
  109. Hsu, 2004, Catheter ablation for atrial fibrillation in congestive heart failure, N Engl J Med, 351, 2373, 10.1056/NEJMoa041018 · DOI
  110. Aryana, 2015, Association between incomplete surgical ligation of left atrial appendage and stroke and systemic embolization, Heart Rhythm, 12, 1431, 10.1016/j.hrthm.2015.03.028 · DOI · Paper page
  111. Boersma, 2017, Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial, Heart Rhythm, 14, 1302, 10.1016/j.hrthm.2017.05.038 · DOI
  112. Lip, 2014, Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial fibrillation (the RHYTHM-AF study), Am J Cardiol, 113, 480, 10.1016/j.amjcard.2013.10.036 · DOI
  113. Airaksinen, 2013, Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study, J Am Coll Cardiol, 62, 1187, 10.1016/j.jacc.2013.04.089 · DOI · Paper page
  114. Dankner, 2009, Treatment of stable atrial fibrillation in the emergency department: a population-based comparison of electrical direct-current versus pharmacological cardioversion or conservative management, Cardiology, 112, 270, 10.1159/000151703 · DOI
  115. Lown, 1967, Electrical reversion of cardiac arrhythmias, Br Heart J, 29, 469, 10.1136/hrt.29.4.469 · DOI
  116. Crijns, 2014, Contemporary real life cardioversion of atrial fibrillation: results from the multinational RHYTHM-AF study, Int J Cardiol, 172, 588, 10.1016/j.ijcard.2014.01.099 · DOI
  117. Stiell, 2011, Variation in management of recent-onset atrial fibrillation and flutter among academic hospital emergency departments, Ann Emerg Med, 57, 13, 10.1016/j.annemergmed.2010.07.005 · DOI
  118. Hindricks, 2021, Eur Heart J, 42, 373, 10.1093/eurheartj/ehaa612 · DOI
  119. Hernandez-Madrid, 2013, Cardioversion for atrial fibrillation in current European practice: results of the European Heart Rhythm Association survey, Europace, 15, 915, 10.1093/europace/eut143 · DOI
  120. Pisters, 2012, Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey, Europace, 14, 666, 10.1093/europace/eur406 · DOI
  121. Brandes, 2020, Cardioversion of atrial fibrillation and atrial flutter revisited: current evidence and practical guidance for a common procedure, Europace, 22, 1149, 10.1093/europace/euaa057 · DOI
  122. Dankner, 2009, Treatment of stable atrial fibrillation in the emergency department: a population-based comparison of electrical direct-current versus pharmacological cardioversion or conservative management, Cardiology, 112, 270, 10.1159/000151703 · DOI
  123. Oral, 1999, Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment, N Engl J Med, 340, 1849, 10.1056/NEJM199906173402401 · DOI
  124. Pedersen, 2001, Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) substudy, Circulation, 104, 292, 10.1161/01.CIR.104.3.292 · DOI · Paper page
  125. Deedwania, 1998, Circulation, 98, 2574, 10.1161/01.CIR.98.23.2574 · DOI
  126. Brembilla-Perrot, 2001, Predictors of atrial flutter with 1:1 conduction in patients treated with class I antiarrhythmic drugs for atrial tachyarrhythmias, Int J Cardiol, 80, 7, 10.1016/S0167-5273(01)00459-4 · DOI
  127. Singh, 2000, Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study, Circulation, 102, 2385, 10.1161/01.CIR.102.19.2385 · DOI · Paper page
  128. Singh, 2005, Amiodarone versus sotalol for atrial fibrillation, N Engl J Med, 352, 1861, 10.1056/NEJMoa041705 · DOI · Paper page
  129. Kober, 2008, Increased mortality after dronedarone therapy for severe heart failure, N Engl J Med, 358, 2678, 10.1056/NEJMoa0800456 · DOI
  130. Singh, 2000, Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study, Circulation, 102, 2385, 10.1161/01.CIR.102.19.2385 · DOI · Paper page
  131. Abraham, 2015, Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter, Circ Arrhythm Electrophysiol, 8, 772, 10.1161/CIRCEP.114.002339 · DOI
  132. Pedersen, 2001, Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy, Circulation, 104, 292, 10.1161/01.CIR.104.3.292 · DOI · Paper page
  133. Alboni, 2004, Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach, N Engl J Med, 351, 2384, 10.1056/NEJMoa041233 · DOI · Paper page
  134. Andrade, 2018, Clinical effectiveness of a systematic "pill-in-the-pocket" approach for the management of paroxysmal atrial fibrillation, Heart Rhythm, 15, 9, 10.1016/j.hrthm.2017.10.002 · DOI
  135. Azpitarte, 1997, Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study, Eur Heart J, 18, 1649, 10.1093/oxfordjournals.eurheartj.a015146 · DOI
  136. Markman, 2022, Safety of pill-in-the-pocket class 1C antiarrhythmic drugs for atrial fibrillation, J Am Coll Cardiol EP, 8, 1515
  137. Singh, 2005, Amiodarone versus sotalol for atrial fibrillation, N Engl J Med, 352, 1861, 10.1056/NEJMoa041705 · DOI · Paper page
  138. Hamilton, 2020, Amiodarone: a comprehensive guide for clinicians, Am J Cardiovasc Drugs, 20, 549, 10.1007/s40256-020-00401-5 · DOI
  139. Tisdale, 2020, Drug-induced arrhythmias: a scientific statement from the American Heart Association, Circulation, 142, e214, 10.1161/CIR.0000000000000905 · DOI
  140. Singh, 2000, Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study, Circulation, 102, 2385, 10.1161/01.CIR.102.19.2385 · DOI · Paper page
  141. Torp-Pedersen, 1999, Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group, N Engl J Med, 341, 857, 10.1056/NEJM199909163411201 · DOI
  142. Ellenbogen, 1996, Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study, J Am Coll Cardiol, 28, 130, 10.1016/0735-1097(96)00121-0 · DOI
  143. Stambler, 1996, Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators, Circulation, 94, 1613, 10.1161/01.CIR.94.7.1613 · DOI
  144. Vardas, 2000, Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study, Chest, 117, 1538, 10.1378/chest.117.6.1538 · DOI
  145. Kochiadakis, 1998, Conversion of atrial fibrillation to sinus rhythm using acute intravenous procainamide infusion, Cardiovasc Drugs Ther, 12, 75, 10.1023/A:1007714203984 · DOI
  146. Stambler, 1997, Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy, Circulation, 96, 4298, 10.1161/01.CIR.96.12.4298 · DOI · Paper page
  147. Singh, 2005, Amiodarone versus sotalol for atrial fibrillation, N Engl J Med, 352, 1861, 10.1056/NEJMoa041705 · DOI · Paper page
  148. Neefs, 2017, Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and meta-analysis, Int J Cardiol, 231, 155, 10.1016/j.ijcard.2016.12.029 · DOI · Paper page
  149. Kowey, 2010, Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial, JAMA, 304, 2363, 10.1001/jama.2010.1735 · DOI · Paper page
  150. Gencer, 2021, Effect of long-term marine -3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis, Circulation, 144, 1981, 10.1161/CIRCULATIONAHA.121.055654 · DOI · Paper page
  151. Andrade, 2021, Cryoablation or drug therapy for initial treatment of atrial fibrillation, N Engl J Med, 384, 305, 10.1056/NEJMoa2029980 · DOI
  152. Pérez, 2009, Long-term outcomes after catheter ablation of cavo-tricuspid isthmus dependent atrial flutter: a meta-analysis, Circ Arrhythm Electrophysiol, 2, 393, 10.1161/CIRCEP.109.871665 · DOI
  153. Disertori, 2011, Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial, Am Heart J, 162, 382, 10.1016/j.ahj.2011.05.008 · DOI
  154. Senoo, 2014, Progression to the persistent form in asymptomatic paroxysmal atrial fibrillation, Circ J, 78, 1121, 10.1253/circj.CJ-13-1272 · DOI
  155. Yang, 2021, Associations of atrial fibrillation progression with clinical risk factors and clinical prognosis: a report from the Chinese Atrial Fibrillation Registry study, J Cardiovasc Electrophysiol, 32, 333, 10.1111/jce.14826 · DOI
  156. Holmqvist, 2015, Heart rate is associated with progression of atrial fibrillation, independent of rhythm, Heart, 101, 894, 10.1136/heartjnl-2014-307043 · DOI
  157. January, 2014, 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society, J Am Coll Cardiol, 64, e1, 10.1016/j.jacc.2014.03.022 · DOI · Paper page
  158. Mark, 2019, Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial, JAMA, 321, 1275, 10.1001/jama.2019.0692 · DOI
  159. Miura, 2020, Treatment strategies and subsequent changes in the patient-reported quality-of-life among elderly patients with atrial fibrillation, Am Heart J, 222, 83, 10.1016/j.ahj.2020.01.011 · DOI
  160. Willems, 2022, Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial, Eur Heart J, 43, 1219, 10.1093/eurheartj/ehab593 · DOI
  161. Packer, 2019, Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial, JAMA, 321, 1261, 10.1001/jama.2019.0693 · DOI
  162. Kirchhof, 2020, Early rhythm-control therapy in patients with atrial fibrillation, N Engl J Med, 383, 1305, 10.1056/NEJMoa2019422 · DOI
  163. Chew, 2022, Diagnosis-to-ablation time predicts recurrent atrial fibrillation and rehospitalization following catheter ablation, Heart Rhythm O2, 3, 23, 10.1016/j.hroo.2021.11.012 · DOI
  164. Di Biase, 2016, Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial, Circulation, 133, 1637, 10.1161/CIRCULATIONAHA.115.019406 · DOI
  165. Marrouche, 2018, Catheter ablation for atrial fibrillation with heart failure, N Engl J Med, 378, 417, 10.1056/NEJMoa1707855 · DOI
  166. Di Biase, 2010, Left atrial appendage: an underrecognized trigger site of atrial fibrillation, Circulation, 122, 109, 10.1161/CIRCULATIONAHA.109.928903 · DOI
  167. Calkins, 2017, 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation, Heart Rhythm, 14, e275, 10.1016/j.hrthm.2017.05.012 · DOI
  168. Packer, 2019, Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial, JAMA, 321, 1261, 10.1001/jama.2019.0693 · DOI
  169. Calkins, 2009, Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses, Circ Arrhythm Electrophysiol, 2, 349, 10.1161/CIRCEP.108.824789 · DOI · Paper page
  170. Blomström-Lundqvist, 2019, Effect of Catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial fibrillation: the CAPTAF randomized clinical trial, JAMA, 321, 1059, 10.1001/jama.2019.0335 · DOI
  171. Packer, 2013, Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial, J Am Coll Cardiol, 61, 1713, 10.1016/j.jacc.2012.11.064 · DOI
  172. Jais, 2008, Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study, Circulation, 118, 2498, 10.1161/CIRCULATIONAHA.108.772582 · DOI
  173. Reynolds, 2018, A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial, J Am Coll Cardiol EP, 4, 580
  174. Packer, 2019, Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial, JAMA, 321, 1261, 10.1001/jama.2019.0693 · DOI
  175. Steinberg, 2015, Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial, Eur Heart J, 36, 288, 10.1093/eurheartj/ehu359 · DOI
  176. Al-Khatib, 2013, Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial, Eur Heart J, 34, 2464, 10.1093/eurheartj/eht135 · DOI
  177. Marrouche, 2018, Catheter ablation for atrial fibrillation with heart failure, N Engl J Med, 378, 417, 10.1056/NEJMoa1707855 · DOI
  178. Piccini, 2012, Outcomes of Medicare beneficiaries undergoing catheter ablation for atrial fibrillation, Circulation, 126, 2200, 10.1161/CIRCULATIONAHA.112.109330 · DOI
  179. Calkins, 2017, 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation, Heart Rhythm, 14, e275, 10.1016/j.hrthm.2017.05.012 · DOI
  180. Campbell, 2020, Sex-based differences in procedural complications associated with atrial fibrillation catheter ablation: a systematic review and meta-analysis, J Cardiovasc Electrophysiol, 31, 3176, 10.1111/jce.14758 · DOI
  181. Russo, 2021, Association between sex and treatment outcomes of atrial fibrillation ablation versus drug therapy: results from the CABANA trial, Circulation, 143, 661, 10.1161/CIRCULATIONAHA.120.051558 · DOI
  182. Noseworthy, 2015, Patterns of anticoagulation use and cardioembolic risk after catheter ablation for atrial fibrillation, J Am Heart Assoc, 4
  183. Santhanakrishnan, 2016, Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction, Circulation, 133, 484, 10.1161/CIRCULATIONAHA.115.018614 · DOI
  184. Rillig, 2021, Early rhythm control therapy in patients with atrial fibrillation and heart failure, Circulation, 144, 845, 10.1161/CIRCULATIONAHA.121.056323 · DOI
  185. Di Biase, 2016, Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial, Circulation, 133, 1637, 10.1161/CIRCULATIONAHA.115.019406 · DOI
  186. MacDonald, 2011, Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial, Heart, 97, 740, 10.1136/hrt.2010.207340 · DOI
  187. Marrouche, 2018, Catheter ablation for atrial fibrillation with heart failure, N Engl J Med, 378, 417, 10.1056/NEJMoa1707855 · DOI
  188. Parkash, 2022, Randomized ablation-based rhythm-control versus rate-control trial in patients with heart failure and atrial fibrillation: results from the RAFT-AF trial, Circulation, 145, 1693, 10.1161/CIRCULATIONAHA.121.057095 · DOI
  189. Turagam, 2019, Catheter ablation of atrial fibrillation in patients with heart failure: a meta-analysis of randomized controlled trials, Ann Intern Med, 170, 41, 10.7326/M18-0992 · DOI
  190. Packer, 2021, Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial, Circulation, 143, 1377, 10.1161/CIRCULATIONAHA.120.050991 · DOI
  191. Khand, 2003, Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?, J Am Coll Cardiol, 42, 1944, 10.1016/j.jacc.2003.07.020 · DOI · Paper page
  192. Kotecha, 2020, Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial, JAMA, 324, 2497, 10.1001/jama.2020.23138 · DOI
  193. Clemo, 1998, Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias, Am J Cardiol, 81, 594, 10.1016/S0002-9149(97)00962-4 · DOI
  194. Delle Karth, 2001, Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias, Crit Care Med, 29, 1149, 10.1097/00003246-200106000-00011 · DOI
  195. Brignole, 1998, Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study, Circulation, 98, 953, 10.1161/01.CIR.98.10.953 · DOI
  196. Kay, 1998, The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. APT Investigators, J Interv Card Electrophysiol, 2, 121, 10.1023/A:1009795330454 · DOI
  197. Weerasooriya, 2003, The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT), J Am Coll Cardiol, 41, 1697, 10.1016/S0735-1097(03)00338-3 · DOI
  198. Nerheim, 2004, Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia, Circulation, 110, 247, 10.1161/01.CIR.0000135472.28234.CC · DOI
  199. Roy, 2008, Rhythm control versus rate control for atrial fibrillation and heart failure, N Engl J Med, 358, 2667, 10.1056/NEJMoa0708789 · DOI · Paper page
  200. Van Gelder, 2010, Lenient versus strict rate control in patients with atrial fibrillation, N Engl J Med, 362, 1363, 10.1056/NEJMoa1001337 · DOI · Paper page

200 of 246 shown

Cited by

Sorted by citations

See all 933

Metadata

Authors
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., Gorenek, B., Hess, P. L., Hlatky, M., Hogan, G., Ibeh, C., Indik, J. H., Kido, K., Kusumoto, F., Link, M. S., Linta, K. T., Marcus, G. M., McCarthy, P. M., Patel, N., Patton, K. K., Perez, M. V., Piccini, J. P., Russo, A. M., Sanders, P., Streur, M. M., Thomas, K. L., Times, S., Tisdale, J. E., Valente, A. M., Van Wagoner, D. R., Krahn, A. D., Andrade, J. G., Beavers, C. J., Bischoff, J. M., Bunch, T. J., Campbell, K. B., Chen, L. Y., Dharia, R., Dorsch, M. P., Gerstenfeld, E. P., Jones, A. E., Kaluzna, S. D., Masha, L., Nault, I., Noseworthy, P. A., Pellegrini, C. N., Tzeis, S. E., Volgman, A. S., & Zeitler, E. P.
Affiliations
  • The University of Texas Southwestern Medical Center (US)
  • Cleveland Clinic Lerner College of Medicine (US)
  • University of Health Sciences and Pharmacy (US)
  • Boston University (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • Temple University Hospital (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • University of Wisconsin–Madison (US)
  • University of Louisville (US)
  • Denver VA Medical Center (US)
  • Stanford Medicine (US)
  • Columbia University Irving Medical Center (US)
  • University of Arizona (US)
  • West Virginia University (US)
  • Mayo Clinic (US)
  • University of California, San Francisco (US)
  • Northwestern Medicine (US)
  • University of Washington (US)
  • Stanford University (US)
  • Duke University (US)
  • Royal Adelaide Hospital (AU)
  • American College of Cardiology (US)
  • Indiana University School of Medicine (US)
  • Brigham and Women's Hospital (US)
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2024-01
Volume
83
Issue
1
Pages
109-279
ISSN
0735-1097 (ISSN-L)
OpenAlex
W4389165660
Cited by
933
References
1,396
Citations by year
2026: 383 · 2025: 336 · 2024: 213
FWCI
183.62
Type
journal article
Language
en
Open access
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion, cc-by-nc)
Funders
  • U.S. Department of Veterans Affairs (IK6 BX006185)
  • National Heart, Lung, and Blood Institute (R01HL158071, P01HL158502)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
Keywords
atrial fibrillation, diagnosis, management, thromboembolic risk assessment, anticoagulation, left atrial appendage closure, catheter ablation, surgical ablation, risk factor control, atrial fibrillation prevention, cardiac arrhythmias
MeSH terms
American Heart Association, Atrial Fibrillation, Cardiology, Humans, Risk Factors, Thromboembolism, United States

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review